CRO Viva could get $749M valuation in Hong Kong listing, Ascentage refiles

Viva would raise HK$1.4 billion ($172.2 million) and be valued at HK$5.9 billion ($748.7 million) if the drug discovery services company prices

Read the full 222 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE